Geoffrey B. Thompson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Geoffrey B. Thompson has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Clive S. Grant
Mayo Clinic
5 shared publications- Clive S. Grant
Mayo Clinic
5 shared publications - Travis J. McKenzie
Department of Surgery, Mayo Clinic, Rochester, USA
5 shared publications William F. Young
Mayo Clinic
5 shared publicationsDavid R. Farley
Department of Surgery, College of Medicine, Mayo Clinic 200 1st St SW, Rochester, MN, 55905, USA
4 shared publications- David R. Farley
Department of Surgery, Mayo Clinic, Rochester, Minnesota
4 shared publications
Latest Publications
- 1 February 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 221 (2) , 455-459
Impact of opioid prescribing guidelines on prescribing at discharge from endocrine surgery
- 1 February 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 221 (2) , 455-459
Impact of opioid prescribing guidelines on prescribing at discharge from endocrine surgery
- 1 July 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (1) , 127-131
Rates of hypercalcemia and hyperparathyroidism among patients with porcelain gallbladder
- 1 July 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (1) , 127-131
Rates of hypercalcemia and hyperparathyroidism among patients with porcelain gallbladder
- 9 May 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (10) , 3851-3857
Bilateral Adrenalectomy: Differences between Cushing Disease and Ectopic ACTH-Producing Tumors
Bilateral adrenalectomy (BA) is a curative treatment for hypercortisolism in patients with corticotropin (ACTH)-dependent Cushing syndrome. Indications inc
- 9 May 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (10) , 3851-3857
Bilateral Adrenalectomy: Differences between Cushing Disease and Ectopic ACTH-Producing Tumors
Bilateral adrenalectomy (BA) is a curative treatment for hypercortisolism in patients with corticotropin (ACTH)-dependent Cushing syndrome. Indications inc
- Open Access
- 6 September 2018
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 2 (11) , 1226-1235
Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience
Context Amiodarone induced thyrotoxicosis (AIT) is a difficult diagnostic and management challenge, especially during severe thyrotoxicosis accompanied by cardiovascular compromise. Objective: We aimed to evaluate thyroidectomy for the management of AIT. Design Retrospective cohort study of adults with non-congenital heart disease with AIT after > 3 months of amiodarone that underwent thyroidectomy from 11/1/2002 - 12/31/2016. Setting Referral center. Patients The group comprised of 17 patients. Main Outcome Measures Thyroid function, left ventricular ejection fraction (LVEF) and surgical complications were the main outcome measures. Results Patients had median age of 60 years, 82.4% were males and 47% had systolic heart failure. At diagnosis, median TSH was 0.005 mIU/L, median free T4 3.25 ng/dL and total T3 198.5 ng/dL. We classified 5 each as type 1 and type 2, 2 as mixed; 5 remained undefined. The most common surgical indications were medically refractory disease, worsening cardiac status and severe thyrotoxicosis requiring prompt resolution. Within 1 week post-thyroidectomy, median TSH was 0.565 mIU/L and free T4 1.8 ng/dL. Median LVEF improved by 8% in the patients with systolic heart failure. 7 patients had a complication within 30 days post-surgery including re-hospitalization (n=4), cervical hematoma (n=2), recurrent arrhythmia (n=2), symptomatic hypocalcemia (n=1); death (n=1). A larger thyroid gland was a risk factor for complications. Conclusions Thyroidectomy resulted in rapid resolution of thyrotoxicosis. Its complication rate was higher than for non-AIT indications but lower than previously reported in a similar population of high risk surgical patients.
- 6 September 2018
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 2 (11) , 1226-1235
Open AccessThyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience
Context Amiodarone induced thyrotoxicosis (AIT) is a difficult diagnostic and management challenge, especially during severe thyrotoxicosis accompanied by cardiovascular compromise. Objective: We aimed to evaluate thyroidectomy for the management of AIT. Design Retrospective cohort study of adults with non-congenital heart disease with AIT after > 3 months of amiodarone that underwent thyroidectomy from 11/1/2002 - 12/31/2016. Setting Referral center. Patients The group comprised of 17 patients. Main Outcome Measures Thyroid function, left ventricular ejection fraction (LVEF) and surgical complications were the main outcome measures. Results Patients had median age of 60 years, 82.4% were males and 47% had systolic heart failure. At diagnosis, median TSH was 0.005 mIU/L, median free T4 3.25 ng/dL and total T3 198.5 ng/dL. We classified 5 each as type 1 and type 2, 2 as mixed; 5 remained undefined. The most common surgical indications were medically refractory disease, worsening cardiac status and severe thyrotoxicosis requiring prompt resolution. Within 1 week post-thyroidectomy, median TSH was 0.565 mIU/L and free T4 1.8 ng/dL. Median LVEF improved by 8% in the patients with systolic heart failure. 7 patients had a complication within 30 days post-surgery including re-hospitalization (n=4), cervical hematoma (n=2), recurrent arrhythmia (n=2), symptomatic hypocalcemia (n=1); death (n=1). A larger thyroid gland was a risk factor for complications. Conclusions Thyroidectomy resulted in rapid resolution of thyrotoxicosis. Its complication rate was higher than for non-AIT indications but lower than previously reported in a similar population of high risk surgical patients.
- Open Access
- 1 January 2018
- Published by XMLink in The Journal of Advanced Prosthodontics
- Vol. 10 (6) , 430-439
Advancements in craniofacial prosthesis fabrication: A narrative review of holistic treatment
Jazayeri HE, et al. J Adv Prosthodont. 2018 Dec;10(6):430-439. https://doi.org/10.4047/jap.2018.10.6.430
- 1 January 2018
- Published by XMLink in The Journal of Advanced Prosthodontics
- Vol. 10 (6) , 430-439
Open AccessAdvancements in craniofacial prosthesis fabrication: A narrative review of holistic treatment
Jazayeri HE, et al. J Adv Prosthodont. 2018 Dec;10(6):430-439. https://doi.org/10.4047/jap.2018.10.6.430
- 1 January 2017
- Published by AME Publishing Company in Mediastinum
- Vol. 1 (9) , AB040
AB040. PS02.04: DOTATATE PET/CT in thymic atypical carcinoid tumor with secondary ACTH-dependent Cushing’s syndrome
Neuroendocrine thymic tumors represent the least common type of primary thymic tumor with a prevalence of 2–5%. We present a case of locally advanced thymic atypical carcinoid tumor diagnosed incidentally while investigating progressive Cushing’s syndrome. CT scan demonstrated a large 2.9 cm exophytic thyroid nodule and a 2.0 cm anterior mediastinal mass. Biopsy of the thyroid nodule demonstrated benign thyroid tissue, and Octreotide scan revealed avid uptake in the right thyroid lobe with minimal uptake in the thymic tumor. 68-Gallium DOTATATE PET-CT scan showed intense uptake in the thyroid gland followed by a moderate amount of activity in the anterior mediastinal mass. The patient underwent a median sternotomy and radical thymectomy with en bloc resection of the left innominate vein and primary repair of the superior vena cava. On further evaluation, the presumed thyroid nodule appeared contiguous with the thymic lesion and separate from the thyroid. Final pathology demonstrated a poorly differentiated 4.4 cm atypical carcinoid tumor with nine positive lymph nodes. On the third postoperative day, the serum cortisol level precipitously decreased to a level of 6.8 µg/dL. This case highlights the challenges surrounding the diagnosis of hormonally active thymic carcinoids, and demonstrates the utility of 68-Gallium DOTATATE PET scan in localizing somatostatin-positive neuroendocrine tumors, and surgical planning.
- 1 January 2017
- Published by AME Publishing Company in Mediastinum
- Vol. 1 (9) , AB040
AB040. PS02.04: DOTATATE PET/CT in thymic atypical carcinoid tumor with secondary ACTH-dependent Cushing’s syndrome
Neuroendocrine thymic tumors represent the least common type of primary thymic tumor with a prevalence of 2–5%. We present a case of locally advanced thymic atypical carcinoid tumor diagnosed incidentally while investigating progressive Cushing’s syndrome. CT scan demonstrated a large 2.9 cm exophytic thyroid nodule and a 2.0 cm anterior mediastinal mass. Biopsy of the thyroid nodule demonstrated benign thyroid tissue, and Octreotide scan revealed avid uptake in the right thyroid lobe with minimal uptake in the thymic tumor. 68-Gallium DOTATATE PET-CT scan showed intense uptake in the thyroid gland followed by a moderate amount of activity in the anterior mediastinal mass. The patient underwent a median sternotomy and radical thymectomy with en bloc resection of the left innominate vein and primary repair of the superior vena cava. On further evaluation, the presumed thyroid nodule appeared contiguous with the thymic lesion and separate from the thyroid. Final pathology demonstrated a poorly differentiated 4.4 cm atypical carcinoid tumor with nine positive lymph nodes. On the third postoperative day, the serum cortisol level precipitously decreased to a level of 6.8 µg/dL. This case highlights the challenges surrounding the diagnosis of hormonally active thymic carcinoids, and demonstrates the utility of 68-Gallium DOTATATE PET scan in localizing somatostatin-positive neuroendocrine tumors, and surgical planning.
- 6 July 2016
- Published by Wiley in World Journal of Surgery
- Vol. 40 (12) , 2956-2963
Selective Parathyroid Hormone Venous Sampling in Patients with Persistent or Recurrent Primary Hyperparathyroidism and Negative, Equivocal or Discordant Noninvasive Imaging
Background: In patients with persistent (P‐PHPT) or recurrent (R‐PHPT) primary hyperparathyroidism, preoperative localization is important. Selective parathyroid hormone venous sampling (sPVS) is an invasive technique that can be used to regionalize and/or lateralize the source of PHPT when noninvasive imaging studies are nonlocalizing. The aim of the present study was to assess the role of sPVS in the preoperative evaluation of patients with P‐PHPT or R‐PHPT and negative, equivocal, or discordant noninvasive imaging localization.Methods: After IRB‐approval a retrospective review of all patients with P‐PHPT or R‐PHPT and nonlocalizing noninvasive imaging that underwent sPVS from 2000 to 2014 was performed. The location of the source of PHPT at sPVS was predicted by a parathyroid hormone (PTH) gradient and compared to the surgical, pathology, and biochemical follow‐up data as the gold standard. Sensitivity and positive predictive value (PPV) were calculated.Results: Of 30 patients who underwent sPVS, 12 patients did not undergo surgical exploration due to negative or non‐localizing PTH gradient (n = 8) or opted for medical management (n = 4). Of the 18 patients who underwent surgical exploration, 17 (94 %) had a positive PTH gradient and pathologic parathyroid tissue identified at surgery. Sensitivity and PPV of sPVS were 93 and 77 %, respectively, for all surgical cases, 86 and 60.0 % for cervical cases (n = 11), and 100 and 100 % for mediastinal cases (n = 7). Sixteen patients (89 %) were surgically cured.Conclusions: In patients with P‐PHPT or R‐PHPT and nonlocalizing imaging studies, sPVS is a sensitive test for localizing the source of PHPT when a positive PTH gradient is present.
- 6 July 2016
- Published by Wiley in World Journal of Surgery
- Vol. 40 (12) , 2956-2963
Selective Parathyroid Hormone Venous Sampling in Patients with Persistent or Recurrent Primary Hyperparathyroidism and Negative, Equivocal or Discordant Noninvasive Imaging
Background: In patients with persistent (P‐PHPT) or recurrent (R‐PHPT) primary hyperparathyroidism, preoperative localization is important. Selective parathyroid hormone venous sampling (sPVS) is an invasive technique that can be used to regionalize and/or lateralize the source of PHPT when noninvasive imaging studies are nonlocalizing. The aim of the present study was to assess the role of sPVS in the preoperative evaluation of patients with P‐PHPT or R‐PHPT and negative, equivocal, or discordant noninvasive imaging localization.Methods: After IRB‐approval a retrospective review of all patients with P‐PHPT or R‐PHPT and nonlocalizing noninvasive imaging that underwent sPVS from 2000 to 2014 was performed. The location of the source of PHPT at sPVS was predicted by a parathyroid hormone (PTH) gradient and compared to the surgical, pathology, and biochemical follow‐up data as the gold standard. Sensitivity and positive predictive value (PPV) were calculated.Results: Of 30 patients who underwent sPVS, 12 patients did not undergo surgical exploration due to negative or non‐localizing PTH gradient (n = 8) or opted for medical management (n = 4). Of the 18 patients who underwent surgical exploration, 17 (94 %) had a positive PTH gradient and pathologic parathyroid tissue identified at surgery. Sensitivity and PPV of sPVS were 93 and 77 %, respectively, for all surgical cases, 86 and 60.0 % for cervical cases (n = 11), and 100 and 100 % for mediastinal cases (n = 7). Sixteen patients (89 %) were surgically cured.Conclusions: In patients with P‐PHPT or R‐PHPT and nonlocalizing imaging studies, sPVS is a sensitive test for localizing the source of PHPT when a positive PTH gradient is present.